Chronic Kidney Disease (CKD) Therapeutics

Sept. 15, 2011 - PRLog -- GlobalData estimates that the major markets (the US, the UK, Germany, France, Italy, Spain and Japan)
for chronic kidney disease (CKD) were valued at $7.1 billion in 2010, and forecasts this to grow at a Compound Annual Growth Rate (CAGR) of 6.4%, to reach $11.6 billion by 2018. This modest growth forecast is primarily attributed to the currently approved drugs reaching their peak sales, followed by the launch of first-in-class molecules in the forecast period. The existing market is moderate, with significant unmet need as the treatment options presently available to treat CKD are only for symptomatic relief and the market lacks targeted therapies.

GlobalData has found that the CKD therapeutics market has significant unmet needs, which implies that
the market is moderately served by the current products in terms of efficacy and safety, and that there is a good scope for new entrants. CKD therapies are largely targeted at reducing the inflammation, serum phosphorus and proteinuria levels through blood pressure control. The market is dominated by generics and off-label medications, which include antihypertensive and anti-diabetic agents, immunosuppressive agents, corticosteroids and antibiotics. The safety and efficacy profiles of phosphate binders, immunosuppressive agents and corticosteroids used are moderate, thereby generating a significant unmet need. The drugs currently prescribed aim at reducing inflammation, proteinuria and serum phosphorus levels, but there are no drugs that can completely stop proteinuria and restore normal kidney function in terms of the glomerular filtration rate. Thus, the market awaits a drug that could change the course of the disease. The potential for any drug that could change the course of the disease is high. As a result, there is a significant need for novel drugs to change the current treatment scenario. New molecular targeted therapies, if successfully developed, would become blockbuster drugs in the market. In summary, the CKD market is expected to be a relatively open market for new entrants until 2018, with many opportunities for value capture.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

The pipeline of CKD consists of 35 molecules in various phases of clinical development, including 12 firstin- class (FIC) molecules, out of which seven molecules are in Phase III stage of clinical development and two are in pre-registration. The FIC Phase III pipeline includes PA21, Bardoxolone methyl (RTA 402),
Beraprost Sodium (YM533) and Kremezin (MP-146). These molecules are expected to drive the market in the forecast period. The Phase II FIC molecules are not likely to hit the market during the forecast period. Some of these FIC molecules have distinct advantages over the currently marketed products for CKD in terms of providing better efficacy.

GlobalData, the industry analysis specialist, has released its new report, “Chronic Kidney Disease (CKD) Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global CKD market. The report identifies the key trends shaping and driving the global CKD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CKD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Chro...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.